^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | berubicin (RTA 744) (Topoisomerase II inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme
Published date:
06/29/2021
Excerpt:
CNS Pharmaceuticals, Inc...today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for its lead investigational drug, Berubicin, for the treatment of patients with recurrent glioblastoma multiforme (GBM).
